Early Prostate Cancer Antigen-2: a Novel Serum Specific Marker for Prostate Cancer Detection

Early Prostate Cancer Antigen-2 (EPCA-2) is a prostate cancer biomarker, newly identified via proteomics-based examination of alterations in nuclear structure. EPCA-2 shows a higher overall specificity than PSA. Thus, an immunoassay based on antibodies against an epitope of EPCA-2 more accurately differentiates between confined and non-confined disease than PSA or Gleason score.

Attached files:
WO 2009134338.jpg

Patents:
WO 2,009,134,338

Inventor(s): GETZENBERG ROBERT H [US]

Type of Offer: Licensing

Contact Patent Owner or Broker


Next Patent »
« More Biotech Patents

Share on      

CrowdSell Your Patent